Current Role of Platelet Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes
Article Abstract:
Intravenous infusions of glycoprotein IIb/IIIa receptor antagonists may be beneficial for patients having a heart attack or severe angina. These drugs prevent blood clot formation, which is the cause of most heart attacks.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Thrombolytic therapy of acute myocardial infarction: keeping the unfulfilled promises
Article Abstract:
Thrombolytic therapy may be used to prevent another heart attack in patients who have already suffered a severe heart attack. Thrombolytic therapy is treatment with different drugs to break up blood clots. A survey of the medical literature found that thrombolytic therapy can significantly decrease the number of complications and deaths among patients who have suffered a severe heart attack. Many patients who would benefit from this type of treatment do not receive it for a variety of reasons. Patients with high blood pressure or who have received cardiopulmonary resuscitation (CPR) often do not receive thrombolytic therapy, even though these conditions only slightly decrease their chance of benefiting from treatment. Elderly patients who have had a heart attack should not excluded from treatment on the basis on their age.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1992
User Contributions:
Comment about this article or add new information about this topic:
Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/ IIIa blockade during percutaneous coronary revascularization
Article Abstract:
The efficacy of bivalirudin that remains comparable with that of heparin plus Gp IIb/IIIa blockade over six months and one year are described. The result indicates that long-term clinical outcome with bivalirudin and provisional Gp IIb/IIa blockade is comparable with that of heparin plus planned Gp IIb/IIa inhibition during contemporary percutaneous coronary intervention.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization
- Abstracts: Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. Whole Grain Consumption and Risk of Ischemic Stroke in Women: A Prospective Study